Skip to main content

Table 1 Summary of the included records

From: Effectiveness of naltrexone treatment for alcohol use disorders in HIV: a systematic review

No

Authors, year

Type of study

No of Participants

Intervention

Time of evaluation

Outcome

1

Cook et al. 2017 [44]

Randomized clinical trial

17

Oral Naltrexone (50 mg) for 4 month

2, 4 and 7 months

82% of participants completed the 7-month assessment. Alcohol use was reduced substantially in both groups.

2

Edelman et al. 2019 [45]

Randomized controlled trial

51

XR-NTX*, 380 mg (4 mL) injection for 24 weeks

12, 24,32 and 56 months

The XR-NTX had no effect on ART adherence and HIV markers. XR-NTX was associated with fewer heavy drinking days.

3

Korthuis et al. 2017b [46]

Pilot study

29

XR-NTX injection for 8 month

16 weeks

Mean days of drinking to intoxication in the past 30 days was decreased. HIV viral suppression was improved

4

Korthuis et al. 2017a [47]

Pilot/ Feasibility Randomized Trial

27

XR-NTX 380 mg for 16 months

16 weeks

Mean heavy drinking days was decreased. HIV suppression was improved.

5

Springer et al. 2017

Randomized, double-blind, placebo-controlled trial

100

XR-NTX for 6 month

6 month

There was no significant differences between groups for drinking outcomes.

6

Springer et al. 2018 [48]

Double blind randomized placebo-controlled trial

100

XR-NTX for 6 month

6 month

The XR-NTX has improved or maintain the viral suppression (VS).

7

Hu et al. 2013 [49]

Double-blind, randomized controlled trial

19

Oral Naltrexone (50 mg) for 4 month

2, 4 and 7 months

Average daily alcohol consumption was reduced.